About MPN Research Foundation
Be part of the solution
Patients, clinicians, researchers, and the biotech and pharma industries all have critical roles to play in advancing MPN research and are all important members of the MPNRF community.
Patients & caregivers
Every patient experience is unique and provides new clues for researchers and clinicians. Begin your journey with MPNRF by sharing your story.
Researchers & clinicians
In our over 25-year history, MPNRF has contributed to some of the most influential MPN discoveries. Learn more about our resources for clinicians and researchers and apply for funding.
Industry
Engage with us to ensure that new therapies in development address the unmet needs of MPN patients, and improve patient outcomes and quality of life. Participate in our MPN Roundtable™ or read our Voice of the Patient report.
Join the MPN Research community
MPN Research Foundation is dedicated to funding and advancing original research in pursuit of new treatments — and eventually a cure — for essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF), blood cancers known collectively as myeloproliferative neoplasms (MPNs).
Founded in 1999, MPN Research Foundation was the first organization in the MPN space, and is the primary, global organization focused on advancing research.
From our unique position at the intersection among key stakeholders — patients and caregivers, researchers and clinicians and the biopharmaceutical industry — MPN Research Foundation facilitates a collaborative approach to research that elevates the patient voice in research and drug development, brings disease experts together, and accelerates the industry’s understanding of an extremely complex group of diseases.
Learn more about our Founder, Bob Rosen, and the MPNRF mission and history.
Our research philosophy and impact
MPN Research Foundation takes a portfolio approach to high-risk, high-reward research to achieve the greatest impact with its funding. Our organization is small but mighty, leveraging funding in 3 ways:
- Agile — MPN Research Foundation remains agile by adapting to emerging opportunities that arise organically through connections in the community. These are often smaller investments with shorter timelines.
- Deliberate — MPN Research Foundation is deliberate in its requests for applications to the research community with defined criteria and predictable cycles.
- Sustained — MPN Research Foundation looks to the horizon for what’s next with initiatives that need a long-term, multi-year, multi-collaborator approach.
In evaluating promising research to fund, we execute a robust, peer-review process that mirrors the NIH. We leverage the experts in the field to score and make recommendations to the MPNRF board.
As a result, we have a proven track record of investing in impactful research expanding MPN knowledge in the laboratory and clinic. Among studies funded between 2014 and 2019:
- 70% achieved outcomes that attracted follow-on funding
- 79% resulted in a peer-reviewed publication
- 42% involved assets that advanced to the clinic directly from the investigation or were a pre-clinical candidates preparing for trials. *As of Q1 2023
